Phathom Pharmaceuticals (NASDAQ:PHAT) Coverage Initiated by

Stifel Nicolaus initiated coverage on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a report released on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $24.00 price objective on the stock. Separately, Needham & Company LLC restated a buy rating and set a $26.00 price objective on shares of Phathom […]

Related Keywords

Ohio , United States , China , Canada , Molly Henderson , Terrie Curran , Stifel Nicolaus , Zurcher Kantonalbank Zurich Cantonalbank , Phathom Pharmaceuticals , Phathom Pharmaceuticals Inc , China Universal Asset Management Co , Analyst Recommendations For Phathom Pharmaceuticals , Phathom Pharmaceuticals Trading , Needham Company , Securities Exchange Commission , Klingman Associates , Hedge Funds Weigh In On Phathom Pharmaceuticals , News Ratings For Phathom Pharmaceuticals Daily , Phathom Pharmaceuticals Company Profile , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Universal Asset Management , Kantonalbank Zurich Cantonalbank , Employees Retirement System , Phathom Pharmaceuticals Daily , Nasdaq Phat , Uphat , Medical , Initiated Coverage ,